The company has a looming opportunity to grab the booming GLP-1 agonist market by the horns.

While you may be more familiar with brand names such as Ozempic or Wegovy, these drugs are known as glucagon-like peptide-1 (GLP-1) agonists in the medical world. Eli Lilly ( LLY -0.50%) has emerged ...

One of the largest mergers or acquisitions in the past year brought a new corporate citizen to southeastern Wisconsin and ...

In a report released today, Geoff Meacham from Citi maintained a Buy rating on Eli Lilly & Co (LLY – Research Report). The company’s shares closed yesterday at $821.67. Easily identify stocks ...

Eli Lilly on Thursday expanded its direct-to-consumer online platform LillyDirect to include telehealth providers to diagnose ...

(RTTNews) - Eli Lilly and Company (LLY) has expanded its LillyDirect digital healthcare platform to offer connections to independent in-person and telehealth options for people in the U.S. living ...

After failing to pass muster with England’s drug reimbursement watchdog earlier this month, Eli Lilly’s Alzheimer’s disease med Kisunla (donanemab) also got a rejection from EU regulators.

Eli Lilly has said it is seeking ... according to an Irish Examiner report. The plant will be used to "support increased demand for existing Lilly products and play a key role in bringing Lilly's ...

Eli Lilly and Company (NYSE: LLY) today announced positive Phase 2 results for lepodisiran, an investigational small interfering RNA (siRNA) therapy designed to lower the production of lipoprotein ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. The EU’s medicines regulator has declined to approve Eli Lilly’s new Alzheimer’s drug, deciding the ...

After starting 2024 strong, Eli Lilly (NYSE: LLY) did not perform well in the second half of last year. Its financial results, though solid compared to similarly sized peers, were not always up to ...